Tff Pharmaceuticals Inc (NASDAQ: TFFP)’s stock price has gone rise by 23.81 in comparison to its previous close of 0.23, however, the company has experienced a 25.99% increase in its stock price over the last five trading days. Seeking Alpha reported 2023-11-14 that TFF Pharmaceuticals, Inc. (NASDAQ:TFFP ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Corey Davis – IR, LifeSci Advisors Harlan Weisman – CEO Zamaneh Mikhak – Chief Medical Officer Kirk Coleman – CFO Conference Call Participants Jonathan Aschoff – ROTH MKM Justin Walsh – JonesTrading Daniel Carlson – Tailwinds Operator Good afternoon, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is being recorded.
Is It Worth Investing in Tff Pharmaceuticals Inc (NASDAQ: TFFP) Right Now?
and a 36-month beta value of 1.10.
The public float for TFFP is 53.33M, and at present, short sellers hold a 0.03% of that float. On November 20, 2023, the average trading volume of TFFP was 124.18K shares.
TFFP’s Market Performance
TFFP’s stock has seen a 25.99% increase for the week, with a -13.51% drop in the past month and a -29.37% fall in the past quarter. The volatility ratio for the week is 25.03%, and the volatility levels for the past 30 days are at 14.04% for Tff Pharmaceuticals Inc The simple moving average for the past 20 days is 2.38% for TFFP’s stock, with a -44.32% simple moving average for the past 200 days.
Analysts’ Opinion of TFFP
Many brokerage firms have already submitted their reports for TFFP stocks, with H.C. Wainwright repeating the rating for TFFP by listing it as a “Buy.” The predicted price for TFFP in the upcoming period, according to H.C. Wainwright is $22 based on the research report published on May 19, 2022 of the previous year 2022.
TFFP Trading at -10.53% from the 50-Day Moving Average
After a stumble in the market that brought TFFP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.91% of loss for the given period.
Volatility was left at 14.04%, however, over the last 30 days, the volatility rate increased by 25.03%, as shares sank -15.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.14% lower at present.
During the last 5 trading sessions, TFFP rose by +25.99%, which changed the moving average for the period of 200-days by -69.05% in comparison to the 20-day moving average, which settled at $0.2758. In addition, Tff Pharmaceuticals Inc saw -72.86% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at TFFP starting from CARLSON CAPITAL L P, who sale 1,000 shares at the price of $0.39 back on Aug 16. After this action, CARLSON CAPITAL L P now owns 5,064,000 shares of Tff Pharmaceuticals Inc, valued at $392 using the latest closing price.
Weisman Harlan F, the President and CEO of Tff Pharmaceuticals Inc, purchase 600,000 shares at $0.25 during a trade that took place back on Aug 15, which means that Weisman Harlan F is holding 814,615 shares at $150,000 based on the most recent closing price.
Stock Fundamentals for TFFP
The total capital return value is set at -104.49, while invested capital returns managed to touch -102.94. Equity return is now at value -150.43, with -135.87 for asset returns.
Based on Tff Pharmaceuticals Inc (TFFP), the company’s capital structure generated 0.83 points at debt to equity in total, while total debt to capital is 0.83. Total debt to assets is 0.79, with long-term debt to equity ratio resting at 0.48. Finally, the long-term debt to capital ratio is 0.48.
The liquidity ratio also appears to be rather interesting for investors as it stands at 16.83.
To sum up, Tff Pharmaceuticals Inc (TFFP) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.